MHRA (UK)Original article
Class 4 Medicines Defect Notification: Neuraxpharm UK Ltd, Tuzulby prolonged-release chewable tablets, EL(26)A/36
RegulatoryTuzulbyNegative
AI Analysis
Summary
Neuraxpharm UK Ltd notified the MHRA of missing safety information in patient documentation for certain batches of Tuzulby prolonged-release chewable tablets, resulting in a Class 4 medicines defect notification.
Outcome Details
Class 4 medicines defect notification for missing safety information in Patient Information Leaflet and Summary of Product Characteristics for certain batches of Tuzulby prolonged-release chewable tablets (20mg, 30mg, 40mg)
Importance:4/10
Sentiment:
-0.60
regulatory_defectsafety_informationproduct_qualityUK_MHRAclass_4_notification
Read the original article
Published by MHRA (UK) on July 23, 2026 10:03 AM